Three Sides to the Story: Adherence Trajectories During the First Year of SGLT2 Inhibitor Therapy Among Medicare Beneficiaries.
Chelsea E HawleyJulie C LauffenburgerJulie M PaikDeborah J WexlerSeoyoung C KimElisabetta PatornoPublished in: Diabetes care (2022)
In a large population of older patients with type 2 diabetes, 45% were highly adherent during the first year of SGLT2i treatment. Female sex and Black race/ethnicity were most strongly associated with low adherence.